Subsidiary of Tibet Weixinkang Pharmaceutical (603676.SH) Obtained Registration Certificate for Acetylcysteine Inhalation Solution Drug.

Xizang Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Yangpu Jingtai Pharmaceutical Co., Ltd. (referred to as "Yangpu Jingtai") recently received the Drug Registration Certificate for Inhalation Acetylcysteine Solution issued by the National Medical Products Administration. Inhalation Acetylcysteine Solution is a mucolytic agent used to treat respiratory diseases with excessive thick mucus secretion, such as acute bronchitis, chronic bronchitis and exacerbations, emphysema, mucus obstruction, and bronchiectasis. As of December 31, 2024, the cumulative research and development investment in this drug is approximately RMB 7.0816 million (unaudited).